Rhoen Klinikum (RHK) Given a €25.50 Price Target by Warburg Research Analysts

Warburg Research set a €25.50 ($29.65) target price on Rhoen Klinikum (ETR:RHK) in a report published on Friday morning. The brokerage currently has a neutral rating on the stock.

Other analysts have also recently issued research reports about the stock. Commerzbank set a €25.00 ($29.07) price objective on shares of Rhoen Klinikum and gave the company a neutral rating in a research report on Friday, November 9th. Berenberg Bank set a €23.50 ($27.33) price objective on shares of Rhoen Klinikum and gave the company a neutral rating in a research report on Wednesday, November 14th. Independent Research set a €24.00 ($27.91) price objective on shares of Rhoen Klinikum and gave the company a neutral rating in a research report on Tuesday, November 13th. Kepler Capital Markets set a €19.00 ($22.09) price objective on shares of Rhoen Klinikum and gave the company a sell rating in a research report on Wednesday. Finally, Cfra set a €22.00 ($25.58) price objective on shares of Rhoen Klinikum and gave the company a sell rating in a research report on Monday, November 12th. Four investment analysts have rated the stock with a sell rating and four have given a hold rating to the company’s stock. The company has an average rating of Hold and an average target price of €21.75 ($25.29).

ETR:RHK traded up €0.76 ($0.88) during trading hours on Friday, hitting €22.88 ($26.60). The stock had a trading volume of 50,543 shares, compared to its average volume of 43,281. Rhoen Klinikum has a one year low of €25.08 ($29.16) and a one year high of €32.12 ($37.35).

About Rhoen Klinikum

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services primarily in the areas of cardiovascular, neurological disorders, oncology, pneumology, orthopedic, accident, and surgeries; rehabilitation and nursing services to the elderly; and thoracic, tumors, and psychosomatic, as well as spinal, column, and joints diseases.

Featured Story: How Do I Invest in Dividend Stocks

Analyst Recommendations for Rhoen Klinikum (ETR:RHK)

Receive News & Ratings for Rhoen Klinikum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhoen Klinikum and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply